The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant
D Tian, Y Sun, H Xu, Q Ye - Journal of medical virology, 2022 - Wiley Online Library
Recently, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron
variant (B. 1.1. 529) was first identified in Botswana in November 2021. It was first reported …
variant (B. 1.1. 529) was first identified in Botswana in November 2021. It was first reported …
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
A Fendler, EGE de Vries… - Nature Reviews …, 2022 - nature.com
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …
associated mortality than the general population. Owing to this increased risk, patients with …
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort …
T Nyberg, NM Ferguson, SG Nash, HH Webster… - The lancet, 2022 - thelancet.com
Background The omicron variant (B. 1.1. 529) of SARS-CoV-2 has demonstrated partial
vaccine escape and high transmissibility, with early studies indicating lower severity of …
vaccine escape and high transmissibility, with early studies indicating lower severity of …
T cell responses to SARS-CoV-2 spike cross-recognize Omicron
Abstract The SARS-CoV-2 Omicron variant (B. 1.1. 529) has multiple spike protein
mutations, that contribute to viral escape from antibody neutralization,,–and reduce vaccine …
mutations, that contribute to viral escape from antibody neutralization,,–and reduce vaccine …
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
HF Tseng, BK Ackerson, Y Luo, LS Sy, CA Talarico… - Nature medicine, 2022 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B. 1.1. 529)
variant is highly transmissible with potential immune escape. We conducted a test-negative …
variant is highly transmissible with potential immune escape. We conducted a test-negative …
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B. 1.1. 529),
first identified in Botswana and South Africa, may compromise vaccine effectiveness and …
first identified in Botswana and South Africa, may compromise vaccine effectiveness and …
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Abstract The B. 1.1. 529/Omicron variant of SARS-CoV-2 was only recently detected in
southern Africa, but its subsequent spread has been extensive, both regionally and globally …
southern Africa, but its subsequent spread has been extensive, both regionally and globally …
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Abstract The Omicron (B. 1.1. 529) variant of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …
Population immunity and Covid-19 severity with Omicron variant in South Africa
Abstract Background The B. 1.1. 529 (omicron) variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) was first identified on November 25, 2021, in Gauteng …
coronavirus 2 (SARS-CoV-2) was first identified on November 25, 2021, in Gauteng …
[HTML][HTML] Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
The recent emergence of the SARS-CoV-2 Omicron variant is raising concerns because of
its increased transmissibility and its numerous spike mutations, which have the potential to …
its increased transmissibility and its numerous spike mutations, which have the potential to …